Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials

References

• Susanibar-Adaniya S, Barta SK. 2021 Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617–629. doi:10.1002/ajh.26151
   PubMed Web of Science ®Google Scholar
• Harkins RA, Chang A, Patel SP, et al. Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. Expert Rev Hematol. 2019;12(11):959–973. doi:10.1080/17474086.2019.1660159
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2006;109(5):1857–1861. doi:10.1182/blood-2006-08-038257
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–842. doi:10.1182/blood-2013-09-524108
   PubMed Web of Science ®Google Scholar
• Jelicic J, Larsen TS, Maksimovic M, et al. Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review. Crit Rev Oncol Hematol. 2019;133:1–16. doi:10.1016/j.critrevonc.2018.10.006
   PubMed Web of Science ®Google Scholar
• Offner F, Samoilova O, Osmanov E, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015;126(16):1893–1901. doi:10.1182/blood-2015-03-632430
   PubMed Web of Science ®Google Scholar
• Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529–3537. doi:10.1200/JCO.2017.73.3402
   PubMed Web of Science ®Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in Non-Germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295. doi:10.1200/JCO.18.02403
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-Type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(12):1317–1328. doi:10.1200/JCO.20.01366
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Hong F, Scott DW, et al. Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with Non-Germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2017;39(12):1329–1338. doi:10.1200/JCO.2017.73.2784
   Google Scholar
• Harkins RA, Patel SP, Lee MJ, et al. Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based delphi-method survey. Blood Adv. 2022;6(9):2745–2756. doi:10.1182/bloodadvances.2021006504
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ghesquières H, Link BK, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018;36(16):1603–1610. doi:10.1200/JCO.2017.76.5198
   PubMed Web of Science ®Google Scholar
• Loh Z, Salvaris R, Chong G, et al. Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years. Br J Haematol. 2021;193(4):741–749. doi:10.1111/bjh.17436
   PubMed Web of Science ®Google Scholar
• Jelicic J, Larsen TS, Frederiksen H, et al. Statistical challenges in development of prognostic models in diffuse large B-cell lymphoma: comparison between existing Models - A systematic review. Clin Epidemiol. 2020;12:537–555. doi:10.2147/CLEP.S244294
   PubMed Web of Science ®Google Scholar
• Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041–2048. doi:10.1182/blood.2019002729
   PubMed Web of Science ®Google Scholar
• Huang CE, Chen YY, Lu CH, et al. Validation of an enhanced international prognostic index (NCCN-IPI) in an asian cohort of patients with diffuse large B cell lymphoma. Ann Hematol. 2015;94(6):1063–1065. doi:10.1007/s00277-014-2293-8
   PubMed Web of Science ®Google Scholar
• Biccler J, Eloranta S, de Nully Brown P, et al. Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI. Cancer Med. 2018;7(1):114–122. doi:10.1002/cam4.1271
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Jais JP, Ghesquières H, et al. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol. 2016;91(2):179–184. doi:10.1002/ajh.24223
   PubMed Web of Science ®Google Scholar
• Montalbán C, Díaz-López A, Dlouhy I, et al. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β(2) -microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol. 2017;176(6):918–928. doi:10.1111/bjh.14489
   PubMed Web of Science ®Google Scholar
• Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25(1):127–141. doi:10.1002/sim.2331
   PubMed Web of Science ®Google Scholar
• Biccler JL, Eloranta S, de Nully Brown P, et al. Optimizing outcome prediction in diffuse large B-cell lymphoma by use of machine learning and nationwide lymphoma registries: a nordic lymphoma group study. J Clin Oncol Clin Cancer Inform. 2018;2:1–13. doi:10.1200/CCI.18.00025
   PubMed Web of Science ®Google Scholar
• Locke FL, Chou J, Vardhanabhuti S, et al. Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). J Clin Oncol. 2022 40:16_suppl, 7565
   Google Scholar
• Miura K, Konishi J, Miyake T, et al. A host-Dependent prognostic model for elderly patients with diffuse large B-cell lymphoma. Oncologist. 2017;22(5):554–560. doi:10.1634/theoncologist.2016-0260
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011;25(9):1502–1509. doi:10.1038/leu.2011.112
   PubMed Web of Science ®Google Scholar
• Nakayama S, Matsuda M, Adachi T, et al. Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era. Platelets. 2019;30(5):637–645. doi:10.1080/09537104.2018.1499889
   PubMed Web of Science ®Google Scholar
• Sun F, Zhu J, Lu S, et al. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era. BMC Cancer. 2018;18(1):5. doi:10.1186/s12885-017-3931-z
   PubMed Web of Science ®Google Scholar
• Drake MT, Maurer MJ, Link BK, et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol. 2010;28(27):4191–4198. doi:10.1200/JCO.2010.28.6674
   PubMed Web of Science ®Google Scholar
• Tomita N, Sakai R, Fujisawa S, et al. SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma. Cancer Sci. 2012;103(8):1518–1523. doi:10.1111/j.1349-7006.2012.02331.x
   PubMed Web of Science ®Google Scholar
• Ibrahim EM, Refat S, El-Ashwah S, et al. Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors. J Egypt Natl Canc Inst. 2023;35(1):12. doi:10.1186/s43046-023-00171-6
   PubMed Web of Science ®Google Scholar
• Kang J, Yoon S, Suh C. Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Res. 2017;52(4):276–284. doi:10.5045/br.2017.52.4.276
   PubMed Web of Science ®Google Scholar
• Lin RJ, Behera M, Diefenbach CS, et al. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Blood. 2017;130(20):2180–2185. doi:10.1182/blood-2017-05-736975
   PubMed Web of Science ®Google Scholar
• Morrison VA, Hamlin P, Soubeyran P, et al. Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An international society of geriatric oncology (SIOG) expert position paper. J Geriatr Oncol. 2015;6(2):141–152. doi:10.1016/j.jgo.2014.11.004
   PubMed Web of Science ®Google Scholar
• Tao L, Foran JM, Clarke CA, et al. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood. 2014;123(23):3553–3562. doi:10.1182/blood-2013-07-517110
   PubMed Web of Science ®Google Scholar
• Han X, Jemal A, Flowers CR, et al. Insurance status is related to diffuse large B-cell lymphoma survival. Cancer. 2014;120(8):1220–1227. doi:10.1002/cncr.28549
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Tucci A, et al. Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the fondazione italiana linfomi. J Clin Oncol. 2021;39(11):1214–1222. doi:10.1200/JCO.20.02465
   PubMed Web of Science ®Google Scholar
• Vijenthira A, Mozessohn L, Nagamuthu C, et al. Frailty in patients with newly diagnosed diffuse large B-cell lymphoma receiving Curative-Intent therapy: a population-based study. J Natl Compr Canc Netw. 2022;20(6):635–642.e9. doi:10.6004/jnccn.2022.7014
   PubMed Web of Science ®Google Scholar
• Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the international prognostic index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002;99(4):1136–1143. doi:10.1182/blood.v99.4.1136
   PubMed Web of Science ®Google Scholar
• Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the lunenburg lymphoma biomarker consortium. Blood. 2011;117(26):7070–7078. doi:10.1182/blood-2011-04-345256
   PubMed Web of Science ®Google Scholar
• Schmidt-Hansen M, Berendse S, Marafioti T, et al. Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the international prognostic index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review. Leuk Lymphoma. 2017;58(10):2403–2418. doi:10.1080/10428194.2017.1287364
   PubMed Web of Science ®Google Scholar
• Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2017–2022. doi:10.1007/s00259-014-2822-7
   PubMed Web of Science ®Google Scholar
• Xie M, Wu K, Liu Y, et al. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Med Oncol. 2015;32(1):446. doi:10.1007/s12032-014-0446-1
   PubMed Web of Science ®Google Scholar
• Cottereau AS, Nioche C, Dirand AS, et al. 18)F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med. 2020;61(1):40–45. doi:10.2967/jnumed.119.229450
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Dalmasso F, Berchialla P, et al. A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA. EJHaem. 2022;3(2):406–414. doi:10.1002/jha2.421
   PubMedGoogle Scholar
• Eertink JJ, Zwezerijnen GJC, Heymans MW, et al. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood. 2023;141(25):3055–3064. doi:10.1182/blood.2022018558
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845–2853. doi:10.1200/JCO.2018.78.5246
   PubMed Web of Science ®Google Scholar
• Herrera AF, Tracy S, Sehn LH, et al. Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study. J Clin Oncol. 2023;41(16_suppl):7523–7523. doi:10.1200/JCO.2023.41.16_suppl.7523
   Web of Science ®Google Scholar
• Adams HJ, Kwee TC. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;106:55–63. doi:10.1016/j.critrevonc.2016.07.003
   PubMed Web of Science ®Google Scholar
• Burggraaff CN, de Jong A, Hoekstra OS, et al. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46(1):65–79. doi:10.1007/s00259-018-4103-3
   PubMed Web of Science ®Google Scholar
• Shi X, Liu X, Li X, et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and international prognostic index: a multicenter retrospective study. Front Oncol. 2021;11:754964. doi:10.3389/fonc.2021.754964
   PubMed Web of Science ®Google Scholar
• Kong Y, Qu L, Li Y, et al. Predictive significance of a new prognostic score for patients with diffuse large B-cell lymphoma in the interim-Positron emission tomography findings. Medicine. 2016;95(6):e2808. doi:10.1097/MD.0000000000002808
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735–742. doi:10.1038/s41591-022-01731-4
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925–1931. doi:10.1093/eurheartj/ehu207
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511. doi:10.1038/35000501
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dalla-Favera R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol. 2015;52(2):67–76. doi:10.1053/j.seminhematol.2015.01.005
   PubMed Web of Science ®Google Scholar
• Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200–207. doi:10.1200/JCO.2010.30.0368
   PubMed Web of Science ®Google Scholar
• Scott DW. Cell-of-Origin in diffuse large B-cell lymphoma: are the assays ready for the clinic? Am Soc Clin Oncol Educ Book. 2015;35:e458-66–e466. doi:10.14694/EdBook_AM.2015.35.e458
   PubMedGoogle Scholar
• Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010;116(23):4916–4925. doi:10.1182/blood-2010-03-276766
   PubMed Web of Science ®Google Scholar
• Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):649–662. doi:10.1016/S1470-2045(18)30935-5
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407. doi:10.1056/NEJMoa1801445
   PubMed Web of Science ®Google Scholar
• Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020;135(20):1759–1771. doi:10.1182/blood.2019003535
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690. doi:10.1038/s41591-018-0016-8
   PubMed Web of Science ®Google Scholar
• Ennishi D, Jiang A, Boyle M, et al. Double-Hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(3):190–201. doi:10.1200/JCO.18.01583
   PubMed Web of Science ®Google Scholar
• Arthur SE, Jiang A, Grande BM, et al. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat Commun. 2018;9(1):4001. doi:10.1038/s41467-018-06354-3
   PubMedGoogle Scholar
• Blunt DN, Smyth L, Nagamuthu C, et al. Shorter diagnosis-to-treatment interval in diffuse large B-cell lymphoma is associated with inferior overall survival in a large, population-based registry. J Natl Compr Canc Netw. 2021;19(6):719–725. doi:10.6004/jnccn.2020.7654
   PubMed Web of Science ®Google Scholar
• Yoshida M, Nakaya Y, Shimizu K, et al. Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma. Sci Rep. 2021;11(1):2837. doi:10.1038/s41598-021-82615-4
   PubMed Web of Science ®Google Scholar
• Alduaij W, Collinge B, Ben-Neriah S, et al. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood. 2023;141(20):2493–2507.
   PubMed Web of Science ®Google Scholar
• Alig S, Macaulay CW, Kurtz DM, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(23):2605–2616. doi:10.1200/JCO.20.02573
   PubMed Web of Science ®Google Scholar
• Lichtman SM, Harvey RD, Damiette Smit MA, et al. Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical Oncology-Friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group. J Clin Oncol. 2017;35(33):3753–3759. doi:10.1200/JCO.2017.74.4102
   PubMed Web of Science ®Google Scholar
• Lin RJ, Owens CN, Drill E, et al. Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. Haematologica. 2022;107(5):1144–1152. doi:10.3324/haematol.2021.278719
   PubMed Web of Science ®Google Scholar
• Mobadersany P, Yousefi S, Amgad M, et al. Predicting cancer outcomes from histology and genomics using convolutional networks. Proc Natl Acad Sci U S A. 2018;115(13):E2970–e9.
   PubMed Web of Science ®Google Scholar
• Khurana A, Mwangi R, Nowakowski GS, et al. Impact of organ function-based clinical trial eligibility criteria in patients with diffuse large B-cell lymphoma: who gets left behind? J Clin Oncol. 2021;39(15):1641–1649. doi:10.1200/JCO.20.01935
   PubMed Web of Science ®Google Scholar